about
Hepatic phosphatidylethanolamine N-methyltransferase, unexpected roles in animal biochemistry and physiologyRB tumor suppressive function in response to xenobiotic hepatocarcinogensHepatic fat during fasting and refeeding by MRI fat quantification.Hyperpolarized 13C Spectroscopic Evaluation of Oxidative Stress in a Rodent Model of Steatohepatitis.Translational approaches: from fatty liver to non-alcoholic steatohepatitis.Increased diacylglycerols characterize hepatic lipid changes in progression of human nonalcoholic fatty liver disease; comparison to a murine modelHigh-fructose, medium chain trans fat diet induces liver fibrosis and elevates plasma coenzyme Q9 in a novel murine model of obesity and nonalcoholic steatohepatitis.Osthol attenuates hepatic steatosis via decreased triglyceride synthesis not by insulin resistanceExpression, regulation, and triglyceride hydrolase activity of Adiponutrin family members.Liver proteomics in progressive alcoholic steatosis.Hepatoprotective Effect and Synergism of Bisdemethoycurcumin against MCD Diet-Induced Nonalcoholic Fatty Liver Disease in Mice.Auricularia polytricha aqueous extract supplementation decreases hepatic lipid accumulation and improves antioxidative status in animal model of nonalcoholic fatty liver.Injury-dependent retention of intraportally administered mesenchymal stromal cells following partial hepatectomy of steatotic liver does not lead to improved liver recovery6-gingerol protects against nutritional steatohepatitis by regulating key genes related to inflammation and lipid metabolism.Long term highly saturated fat diet does not induce NASH in Wistar rats.Choline and Cystine Deficient Diets in Animal Models with Hepatocellular Injury: Evaluation of Oxidative Stress and Expression of RAGE, TNF-α, and IL-1β.Decreased apoptosis in fatty livers submitted to subnormothermic machine-perfusion respect to cold storage.Erythrophagocytosis by liver macrophages (Kupffer cells) promotes oxidative stress, inflammation, and fibrosis in a rabbit model of steatohepatitis: implications for the pathogenesis of human nonalcoholic steatohepatitis.Altered distribution of regulatory lymphocytes by oral administration of soy-extracts exerts a hepatoprotective effect alleviating immune mediated liver injury, non-alcoholic steatohepatitis and insulin resistance.Administration of anti-receptor activator of nuclear factor-kappa B ligand (RANKL) antibody for the treatment of osteoporosis was associated with amelioration of hepatitis in a female patient with growth hormone deficiency: a case reportLipidomic analysis of lipid droplets from murine hepatocytes reveals distinct signatures for nutritional stress.Mouse models in non-alcoholic fatty liver disease and steatohepatitis research.In Situ Evaluation of Oxidative Stress in Rat Fatty Liver Induced by a Methionine- and Choline-Deficient DietLiver-specific deletion of negative regulator Pten results in fatty liver and insulin hypersensitivity [corrected]High fat diet induces dysregulation of hepatic oxygen gradients and mitochondrial function in vivo.High fat diet induced hepatic steatosis establishes a permissive microenvironment for colorectal metastases and promotes primary dysplasia in a murine modelDifferential expression of microRNAs in mouse liver under aberrant energy metabolic status.Experimental non-alcoholic fatty liver disease results in decreased hepatic uptake transporter expression and function in rats.The transition from fatty liver to NASH associates with SAMe depletion in db/db mice fed a methionine choline-deficient diet.Regulatory effects of arachidonate 5-lipoxygenase on hepatic microsomal TG transfer protein activity and VLDL-triglyceride and apoB secretion in obese mice.S-adenosyl methionine protects ob/ob mice from CYP2E1-mediated liver injury.Blockade of the leptin-sensitive pathway markedly reduces alcohol consumption in mice.Cordyceps militaris alleviates non-alcoholic fatty liver disease in ob/ob mice.Inhibitory effect of Ginkgo biloba extract on fatty liver: regulation of carnitine palmitoyltransferase 1a and fatty acid metabolism.GC-1: A Thyromimetic With Multiple Therapeutic Applications in Liver Disease.The proinflammatory phenotype of PECAM-1-deficient mice results in atherogenic diet-induced steatohepatitis.Effect of insulin-sensitizing agents in combination with ezetimibe, and valsartan in rats with non-alcoholic fatty liver disease.Lycopene prevents development of steatohepatitis in experimental nonalcoholic steatohepatitis model induced by high-fat diet.Molecular pathogenesis of nonalcoholic steatohepatitis: today and tomorrow.Paraoxonase activity and expression is modulated by therapeutics in experimental rat nonalcoholic Fatty liver disease.
P2860
Q28249732-E3030086-7BA8-40BE-98F7-489CB4CBBF78Q28513539-B4DC50C3-A163-4DDD-9E75-C7136977A9A6Q30769371-9941F995-68FA-4F24-9F85-62966BC6577BQ33582800-43B01410-E7F8-4B0A-8E77-0204676C5CC6Q33958697-CDF0459A-986A-4880-A3D0-95B47C6354C8Q33998998-73C6AE7C-1D91-4A87-B79D-FD7A995D9677Q34023013-D4D14621-DE4E-46B2-A344-B343E0AE6EA0Q34137340-9127CB1B-D82C-4885-8442-C200A460754DQ34449398-8E374D3A-E8EE-49FD-94DF-8585B7CECEE3Q34497163-93B87E87-1751-44F0-94FB-39B9A3190C09Q34675761-61E29128-A49E-4F00-95EA-6662B378C8C1Q34691776-90594296-9166-46AB-9968-1ECAC69A4259Q34852908-6CE7F1FB-7AC1-42C9-A4A0-91F670DDDD2BQ35131341-3320E2FF-90A4-4BA2-84B1-4851D3923AF3Q35652085-3C786903-7A4F-4CC2-B6C3-5ABC3B550712Q35744933-1D8466E4-5AB6-4F75-9C32-B0E8422D7690Q35771439-86874FE0-0EFE-48E3-AC31-44DF912B3C60Q35781449-9FC44C9B-75C6-4CC4-A0F7-B23FD4B0071EQ35783896-786929EF-3E13-479F-B6C6-AC869B72D3BFQ36203017-6F179D4B-11DA-47F9-A6F6-2AFC1FCF4EA6Q36213884-855962B6-210D-4696-97D5-534F7E10C3E0Q36377266-38C032D3-5CEC-4987-81E7-08B31A00B060Q36531596-736F7FBB-9FFA-4EE4-8D5F-6566B91CB3BFQ36604703-D1D88879-96E3-4A9A-8A82-A0A4ACF5F5A6Q37087840-F089CD9B-9D6E-4009-A6B1-6D3AFBF89B26Q37257204-BBCED589-2D01-41ED-B63B-EA451C80620CQ37299835-36573728-C215-4D87-89F3-9F757B229066Q37337092-590B7B02-9DE3-4466-88D5-5D293CCEB37AQ37709683-5B939642-AF0F-4171-804D-32AD49D29B47Q38289104-8F75167A-F4A0-4AD3-95A8-9500A183CAA0Q38302560-FC8FCD0A-1629-4B94-9D56-41BB15789EBCQ38334207-4437D722-13B5-45C6-A172-4C21ED9CAFE1Q38781112-53F61F50-43A2-440E-A893-730FAE8641EAQ39276367-B673CBEA-CF1B-4D6C-9276-29D61AEAD57FQ39387787-3DCBE80C-0F91-4B06-B7A7-EDBBE6BDDF85Q40164782-E6188BE4-C1D5-4964-B015-BE8F59810342Q41818240-3F394465-63B1-4852-A2CF-3AF3B2D33FFCQ42075362-EE305153-C1CF-4611-90FB-9F90D87D8E2CQ42430555-5BD5034B-D1E1-424B-920C-5F5209E9AECAQ42554398-F5C680BE-CA46-482F-BC28-F0B020D4F56A
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
name
Animal models of steatohepatitis.
@ast
Animal models of steatohepatitis.
@en
Animal models of steatohepatitis.
@nl
type
label
Animal models of steatohepatitis.
@ast
Animal models of steatohepatitis.
@en
Animal models of steatohepatitis.
@nl
prefLabel
Animal models of steatohepatitis.
@ast
Animal models of steatohepatitis.
@en
Animal models of steatohepatitis.
@nl
P356
P1476
Animal models of steatohepatitis.
@en
P2093
Anna Mae Diehl
Ayman Koteish
P304
P356
10.1053/BEGA.2002.0332
P577
2002-10-01T00:00:00Z